Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Abenroth

Vascular Neurology Boise, ID Medical Doctor

NPI 1053678342 CMS profile 3415771

9Th Floor -- Neurosciences, 190 E Bannock St., Boise, ID 83712

Open in the dashboard

General payments

$676

5 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Abenroth of Boise, ID is reported in the CMS Open Payments database as having received $676 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $484 2
2019 General $192 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Abenroth
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Daniel Abenroth were reported at $0. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Daniel Abenroth Vascular Neurology median Middle half National median
2019 $192 $263 $102–$1,640 $163
2020 $0 $153 $45–$1,000 $114
2021 $0 $261 $100–$1,355 $132
2022 $0 $242 $87–$1,273 $149
2023 $0 $322 $97–$1,266 $160
2024 $484 $247 $70–$1,053 $164
2025 $0 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Qapel Medical Inc $283 1 payment
  2. MicroVention, Inc. $200 1 payment
  3. DePuy Synthes Sales Inc. $126 1 payment
  4. Avanir Pharmaceuticals, Inc. $51 1 payment
  5. Saol Therapeutics Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $625 4 payments
  2. Education $51 1 payment
Products named General payments · program years 2019–2024
  1. WEB ANEURYSM EMBOLIZATION SYSTEM $200 1 payment
  2. ASCENT $126 1 payment
  3. NUEDEXTA $51 1 payment
  4. LIORESAL (BACLOFEN) $15 1 payment
  5. Dysport $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$15,099

Medicare's payments for the services billed

Medicare patients

98

Average age 77

Services billed

158

51 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 39%
Atrial fibrillation 33%
Depression 33%
Ischemic heart disease 32%
Chronic kidney disease 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record